• Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection

• Confirmation of Triple Negative (TN) breast cancer by tissue biopsy

• Adequate tissue to calculate RSI

• To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines

• To fulfill the requirement of hormone receptor (HR)- disease, a breast cancer must express (\<10%), by immunohistochemistry (IHC), the hormone receptors (estrogen receptor \[ER\] and progesterone receptor \[PR\]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines

• Life expectancy \>16 weeks

• KPS ≥ 70

• Age ≥ 18 years

• Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon

• There is no limit on prior systemic therapies

• Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study

• Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before study enrollment